1.09
-0.0106(-0.96%)
Currency In USD
| Previous Close | 1.1 |
| Open | 1.12 |
| Day High | 1.12 |
| Day Low | 1.05 |
| 52-Week High | 392 |
| 52-Week Low | 0.98 |
| Volume | 510,801 |
| Average Volume | 3.8M |
| Market Cap | 5.13M |
| PE | -0.05 |
| EPS | -23 |
| Moving Average 50 Days | 3.78 |
| Moving Average 200 Days | 38.93 |
| Change | -0.01 |
If you invested $1000 in Conduit Pharmaceuticals Inc. (CDT) since IPO date, it would be worth $1.11 as of March 13, 2025 at a share price of $1.1. Whereas If you bought $1000 worth of Conduit Pharmaceuticals Inc. (CDT) shares 2 years ago, it would be worth $1.06 as of March 13, 2025 at a share price of $1.1.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Conduit Pharmaceuticals Provides Update on Nasdaq Stock Market Hearing Panel
GlobeNewswire Inc.
Mar 06, 2025 2:35 PM GMT
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 06, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) announces that, on February 11, 2025, the Company presented its plan
Conduit Progresses Phase II of its AI Initiative with Sarborg
GlobeNewswire Inc.
Feb 20, 2025 1:00 PM GMT
Collaboration reinforces Conduit’s commitment to leveraging AI and cybernetics to reduce human error, lower costs, and accelerate timelines in drug developmentSarborg delivers a prototype AI-product to Conduit’s Management team NAPLES, Fla. and CAMBR
Conduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus Erythematosus Model
GlobeNewswire Inc.
Feb 13, 2025 1:00 PM GMT
Conduit Pharmaceuticals partners with Charles River to evaluate the efficacy of its lead programme in a pre-clinical lupus model, utilizing Charles River’s immunology expertise to refine study parameters and improve probability of successful Phase II